IMVT, Immunovant, Inc

"Loading Stock Price & Valuation Data ..."

Agentic AI (Pro) Picks for IMVT

Subscribe to iPick.ai (Pro) to use Power Picks, Hidden-Gem Picks, and more.


News Summary: Subscribe

Unlock News Summary by Subscribing to iPick.ai Premium!





Unlock Ask IMVT by Subscribing to iPick.ai Premium!



Stock Chart




Latest YouTube Video:

Please Login/Register (click on the top-right button) to see the latest video on IMVT, Immunovant, Inc.

CEO:Dr. Eric Venker M.D., Pharm.D.

Headquarter: 320 West 37th Street, 6th Floor, New York, NY, United States, 10018

Industry: Biotechnology,   Employees: 362

Business Summary

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.